摘要
目的评价阻塞性睡眠呼吸暂停综合征(OSAS)血清细胞间黏附分子-1(ICAM-1)水平及持续气道正压通气治疗(CPAP)对OSAS患者血清ICAM-1水平的影响。方法收集20例健康对照者及20例OSAS患者的临床资料,回顾性分析两组患者多导睡眠呼吸监测结果,比较两组血清ICAM-1水平的差异;比较持续气道正压通气治疗前后OSAS患者血清ICAM-1水平的差异。结果 OSAS组患者治疗前血清ICAM-1含量为(105.26±37.470)μg/L,健康对照组血清ICAM-1含量为(99.98±18.78)μg/L,两组比较差异有统计学意义,P=0.018。经过CPAP治疗3个月后,OSAS组患者血清ICAM-1水平降至(93.34±21.24)μg/L,与治疗前血清ICAM-1水平比较,两组差异有统计学意义,P=0.037。结论 OSAS患者血清ICAM-1水平升高,持续气道正压通气治疗可有效降低OSAS患者血清ICAM-1水平。
Objective To analyze the influence of continuous positive airway pressure（CPAP） on serum intercellular adhesion molecule-1 （ICAM-1） in patients with obstructive sleep apnea syndrome（OSAS）. Methods Clinical data and PSG results were col- lected in 20 patients with OSAS and 20 healthy subjects. Serum ICAM-1 level in all subjects were detected by ELISA method. Re-sults Serum ICAM-1 content in OSAS patients was（105.26±37.47）/xg/L and in healthy controls was （99.98±18.78）μg/L. Ser-um levels of ICAM-1 between the two groups were significantly different（P = 0. 018）. After 3 months treatment of CPAP, serum ICAM-1 level in OSAS patients fell to （93.34 ± 21.24）μg/L, which was significantly different with that before treatment （P=0. 037）. Conclusion Serum ICAM-1 content in OSAS patients might be greatly improved. CPAP treatment could effectively reduce serum ICAM-1 in OSAS patients.
出处
《国际检验医学杂志》
CAS
2013年第4期398-399,401,共3页
International Journal of Laboratory Medicine
基金
首都医学发展科研基金资助项目(2009-3168)
民航总医院科研基金资助项目(200902)
关键词
阻塞性睡眠呼吸暂停
持续气道正压通气
细胞间黏附分子-1
obstructive sleep apnea syndrome
continuous positive airway pressure
intercellular adhesion molecule-1
